AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24973337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vowel auditory training for 6 months
Number of subjects: 30
Study 24973337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 23585292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low caloric preload with consistent calorie information
Number of subjects: 4
Study 23585292 — intervention group
Group type: EXPERIMENTAL
Intervention: High caloric preload with consistent calorie information
Number of subjects: 4
Study 23585292 — intervention group
Group type: COMPARATOR
Intervention: High caloric preload
Number of subjects: 4
Study 21196441 — intervention group
Group type: COMPARATOR
Intervention: CHOP-21
Number of subjects: 323
Study 21196441 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-14
Number of subjects: 323
Study 19218540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified extended dialysis (IED) therapy, dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)
Number of subjects: 156
Study 19218540 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis (SED) therapy, dosed to maintain plasma urea levels between 120 and 150 mg/dL (20‐25 mmol/L)
Number of subjects: 156
Study 17123910 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic jaw exercises (n = 25)
Number of subjects: 55
Study 17123910 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 55
Study 15622365 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice (30-60 minute proctored session)
Number of subjects: 29
Study 15622365 — intervention group
Group type: COMPARATOR
Intervention: No practice
Number of subjects: 29
Study 11376910 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine 0.5 mg/kg bolus followed by 0.25 mg/kg per h (group 3)
Number of subjects: 100
Study 11376910 — intervention group
Group type: COMPARATOR
Intervention: No ketamine (group 1)
Number of subjects: 100
Study 11376910 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine 0.25 mg/kg bolus followed by 0.125 mg/kg per h (group 2)
Number of subjects: 100
Study 11376910 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 0.25 mg/kg and 0.125 mg/kg per h (group 4)
Number of subjects: 100
Study 11376910 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 0.5 mg/kg and 0.25 mg/kg per h (group 5)
Number of subjects: 100
Study 9425677 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological priming
Number of subjects: 0
Study 9425677 — intervention group
Group type: COMPARATOR
Intervention: Legal nonwords
Number of subjects: 0
Study 9425677 — intervention group
Group type: COMPARATOR
Intervention: Pseudohomophone foils
Number of subjects: 0
Study 7683942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (intravenous leucovorin 200 mg/m2/day, 5-fluorouracil 550 mg/m2/day, cisplatin 20 mg/m2/day for four week cycles)
Number of subjects: 40
Study 7683942 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 40
Study 7683942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 40
Study 3828169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl anaesthesia (100 micrograms/kg body weight)
Number of subjects: 0
Study 3828169 — intervention group
Group type: COMPARATOR
Intervention: Balanced type of fentanyl anaesthesia (5 micrograms/kg)
Number of subjects: 0
Study 30735063 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (concentration on the ball) in experiment 1
Number of subjects: 63
Study 30735063 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (focus on the platform) in experiment 2
Number of subjects: 63
Study 30735063 — intervention group
Group type: COMPARATOR
Intervention: Internal focus (concentration on inside of the foot) in experiment 1
Number of subjects: 63
Study 30735063 — intervention group
Group type: COMPARATOR
Intervention: Internal focus (focus on the feet) in experiment 2
Number of subjects: 63
Study 30735063 — intervention group
Group type: COMPARATOR
Intervention: Control (no focus instructions) in both experiments
Number of subjects: 63
Study 29914482 — intervention group
Group type: EXPERIMENTAL
Intervention: RACIPE computational tool for modeling gene regulatory circuits
Number of subjects: 0
Study 29914482 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled toggle-switch circuits and a published circuit of B-lymphopoiesis
Number of subjects: 0
Study 26602782 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sedation interruption plus protocolized sedation (DSI + PS)
Number of subjects: 129
Study 26602782 — intervention group
Group type: COMPARATOR
Intervention: Protocolized sedation only (PS)
Number of subjects: 129
Study 25544955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of ketamine plus 2 mL of bupivacaine 0.5%
Number of subjects: 60
Study 25544955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of normal saline plus 2 mL of bupivacaine 0.5%
Number of subjects: 60
Study 25544955 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of normal saline
Number of subjects: 60
Study 25544955 — intervention group
Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 60
Study 22240782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-cisplatin (GP)
Number of subjects: 433
Study 22240782 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-vinorelbine (N)
Number of subjects: 433
Study 22240782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-ifosfamide-cisplatin (triplet)
Number of subjects: 433
Study 22240782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-ifosfamide-vinorelbine (triplet)
Number of subjects: 433
Study 22240782 — intervention group
Group type: COMPARATOR
Intervention: P-containing therapy
Number of subjects: 433
Study 22240782 — intervention group
Group type: EXPERIMENTAL
Intervention: triplets
Number of subjects: 433
Study 22240782 — intervention group
Group type: COMPARATOR
Intervention: P-containing regimens
Number of subjects: 433
Study 21055287 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG (Group B)
Number of subjects: 506
Study 21055287 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG and early telephonic notification (Group C)
Number of subjects: 506
Study 21055287 — intervention group
Group type: COMPARATOR
Intervention: No prehospital ECG (Group A)
Number of subjects: 506
Study 18681997 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% oxygen
Number of subjects: 1916
Study 18681997 — intervention group
Group type: COMPARATOR
Intervention: 20% oxygen
Number of subjects: 1916
Study 15933509 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral antibiotics
Number of subjects: 7
Study 12075761 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 292
Study 12075761 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (100,000 IU/kg/day in three divided doses for 10 days)
Number of subjects: 292
Study 9534082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BIC)
Number of subjects: 12
Study 9534082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study 7636641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg calcium as calcium citrate malate)
Number of subjects: 101
Study 7636641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no calcium)
Number of subjects: 101
Study 7636641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg calcium as calcium citrate malate) in black subjects
Number of subjects: 101
Study 7636641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg calcium as calcium citrate malate) based on baseline calcium intake quartiles
Number of subjects: 101
Study 2651327 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vasodilators
Number of subjects: 16
Study 2651327 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survival
Number of subjects: 16
Study 336116 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule I: Prednisone plus chlorambucil (CLB) given as a once-a-month dose of 0.4-0.8 mg/kg
Number of subjects: 96
Study 336116 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule II: Prednisone plus chlorambucil (CLB) given as a daily dose of 0.08 mg/kg
Number of subjects: 96
Study 336116 — intervention group
Group type: COMPARATOR
Intervention: Schedule III: Prednisone alone
Number of subjects: 96
Study 27633965 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (arm B)
Number of subjects: 46
Study 27633965 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (arm A)
Number of subjects: 46
Study 26024005 — intervention group
Group type: EXPERIMENTAL
Intervention: Double tunnels technique (DTT)
Number of subjects: 220
Study 26024005 — intervention group
Group type: COMPARATOR
Intervention: Standard open decompression of the median nerve (control)
Number of subjects: 220
Study 23860024 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic reflex therapies (massage, Gua Sha massage, cupping, wet packs, rhythmic embrocation)
Number of subjects: 0
Study 23860024 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic reflex therapies
Number of subjects: 0
Study 21466516 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-step multidisciplinary antenatal care
Number of subjects: 0
Study 21466516 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric antenatal care
Number of subjects: 0
Study 19197206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (1.2 mm, 65 Hz) during exercise with 40% 1RM load
Number of subjects: 11
Study 19197206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (1.2 mm, 65 Hz) during exercise with 70% 1RM load
Number of subjects: 11
Study 19197206 — intervention group
Group type: COMPARATOR
Intervention: Sham vibration during exercise with 40% 1RM load
Number of subjects: 11
Study 19197206 — intervention group
Group type: COMPARATOR
Intervention: Sham vibration during exercise with 70% 1RM load
Number of subjects: 11
Study 16439927 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention
Number of subjects: 100
Study 16439927 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 15526716 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) treatment
Number of subjects: 12
Study 15526716 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 12
Study 15526716 — intervention group
Group type: EXPERIMENTAL
Intervention: Before treatment
Number of subjects: 12
Study 15526716 — intervention group
Group type: EXPERIMENTAL
Intervention: After treatment
Number of subjects: 12
Study 11091828 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ethanol applied to the operative site for three minutes
Number of subjects: 64
Study 11091828 — intervention group
Group type: COMPARATOR
Intervention: Saline applied to the operative site for three minutes (Control)
Number of subjects: 64
Study 11091828 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received the same analgesic protocol including infiltration of the operative site with ropivacaine
Number of subjects: 64
Study 9372359 — intervention group
Group type: EXPERIMENTAL
Intervention: Allylamine preparations and ciclopirox olamine
Number of subjects: 0
Study 9372359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 9372359 — intervention group
Group type: COMPARATOR
Intervention: Oxiconazole, econazole, and 2.5% hydrocortisone
Number of subjects: 0
Study 1403038 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 25 mg/m2/d times three, intravenous (IV) bolus plus cisplatin (CDDP) 100 mg/m2, 24 hour infusion, every 3 weeks times six; preceded by high-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four.
Number of subjects: 198
Study 1403038 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four, followed by Doxorubicin (DOX) and Cisplatin (CDDP).
Number of subjects: 198
Study 3925888 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol I (OK‐432 group)
Number of subjects: 45
Study 3925888 — intervention group
Group type: COMPARATOR
Intervention: Protocol II (non‐OK‐432 group)
Number of subjects: 45
Study 31593709 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg i.v. citalopram
Number of subjects: 32
Study 31593709 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg citalopram
Number of subjects: 32
Study 31593709 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (both dosages)
Number of subjects: 32
Study 30873908 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom cluster (depression, anxiety, fatigue, impaired sleep quality)
Number of subjects: 302
Study 30873908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 302
Study 27723546 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Enabling and Support (IES)
Number of subjects: 61
Study 27723546 — intervention group
Group type: COMPARATOR
Intervention: Traditional vocational rehabilitation (TVR)
Number of subjects: 61
Study 25751386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution group (treatment group)
Number of subjects: 78
Study 25751386 — intervention group
Group type: COMPARATOR
Intervention: Regular diet group (control group)
Number of subjects: 78
Study 23245621 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 2.5mg
Number of subjects: 364
Study 23245621 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 5mg
Number of subjects: 364
Study 23245621 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 20mg
Number of subjects: 364
Study 23245621 — intervention group
Group type: COMPARATOR
Intervention: Optimal standard therapy
Number of subjects: 364
Study 21676008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacobehavioral treatment
Number of subjects: 321
Study 21676008 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 321
Study 21676008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 21676008 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 321
Study 17672828 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) using recombinant human ASB (rhASB)
Number of subjects: 4
Study 16394784 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position intervention
Number of subjects: 0
Study 16394784 — intervention group
Group type: COMPARATOR
Intervention: Control (supine position)
Number of subjects: 0
Study 14959954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate infusion (pamidronate or clodronate)
Number of subjects: 25
Study 14959954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bisphosphonate)
Number of subjects: 25
Study 11000340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 518
Study 11000340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 11000340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 518
Study 8678396 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical and pharmacologic cardioversion
Number of subjects: 0
Study 8678396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic regimens for recent onset atrial fibrillation
Number of subjects: 0
Study 8678396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 0
Study 8678396 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 0
Study 8678396 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 8678396 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/d)
Number of subjects: 0
Study 8678396 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin vs Aspirin in patients older than 75 years
Number of subjects: 0
Study 1363497 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 30
Study 1363497 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 30
Study 1363497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 30
Study 1363497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6693580 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam infusion at two different rates
Number of subjects: 10
Study 6693580 — intervention group
Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 10
Study 2877644 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study 2877644 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg/d)
Number of subjects: 0
Study 2877644 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (50 mg/d)
Number of subjects: 0
Study 2877644 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy with chlorthalidone
Number of subjects: 0
Study 31362691 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0
Study 29877114 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety induction
Number of subjects: 129
Study 29877114 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SAD
Number of subjects: 129
Study 29877114 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 129
Study 28152655 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido (DN) solution
Number of subjects: 59
Study 28152655 — intervention group
Group type: COMPARATOR
Intervention: modified St. Thomas' (MST) cardioplegia solution
Number of subjects: 59
Study 26081016 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 122
Study 26081016 — intervention group
Group type: COMPARATOR
Intervention: Traditional open surgery (TOS)
Number of subjects: 122
Study 23870447 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial training
Number of subjects: 33
Study 23870447 — intervention group
Group type: COMPARATOR
Intervention: Perceptual training
Number of subjects: 33
Study 23870447 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 33
Study 23870447 — intervention group
Group type: COMPARATOR
Intervention: Non-endurance training
Number of subjects: 33
Study 20198403 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartSet HV
Number of subjects: 35
Study 20198403 — intervention group
Group type: COMPARATOR
Intervention: Palacos R
Number of subjects: 35
Study 18197917 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR changes in the exacerbation group
Number of subjects: 36
Study 18197917 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR changes in the spirometric decline group
Number of subjects: 36
Study 18197917 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between FVC or FEV(1) and profusion score
Number of subjects: 36
Study 16458984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling on an ergometric cycle 3 times a week for 30 min for 3 months)
Number of subjects: 17
Study 16458984 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued as they did previously)
Number of subjects: 17
Study 12743862 — intervention group
Group type: EXPERIMENTAL
Intervention: VasoSeal
Number of subjects: 57
Study 12743862 — intervention group
Group type: COMPARATOR
Intervention: Compressar
Number of subjects: 57
Study 11029345 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-corrected group (THAM administered)
Number of subjects: 12
Study 11029345 — intervention group
Group type: COMPARATOR
Intervention: pH-uncorrected group (no THAM administered)
Number of subjects: 12
Study 11029345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 8816034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 100
Study 8816034 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional iron treatment)
Number of subjects: 100
Study 1486738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (1 microgram/day) and 500 mg of calcium
Number of subjects: 36
Study 1486738 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 1486738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (1 microgram/day) continued for a third year
Number of subjects: 36
Study 1486738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (1 microgram/day)
Number of subjects: 36
Study 6535849 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 6535849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 0
Study 6535849 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study 30865304 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure program (cognitive behavioral therapy-based group sessions targeting personality risk profiles)
Number of subjects: 0
Study 30865304 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure program
Number of subjects: 0
Study 30865304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28768270 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education sessions attended by 61 patients (27%)
Number of subjects: 223
Study 28768270 — intervention group
Group type: COMPARATOR
Intervention: Asthma education sessions not attended (non-attenders)
Number of subjects: 223
Study 25576014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recruitment (ER) strategy including personalized outreach, matching parent preferences, and community endorsement
Number of subjects: 256
Study 25576014 — intervention group
Group type: COMPARATOR
Intervention: Standard recruitment (invitation by mail)
Number of subjects: 256
Study 25576014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recruitment (ER) strategy
Number of subjects: 256
Study 23415907 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) in combination with methotrexate (MTX 10 mg/week) and leflunomide (LEF 20 mg/day)
Number of subjects: 204
Study 23415907 — intervention group
Group type: COMPARATOR
Intervention: Control group (MTX 10 mg/week plus LEF 20 mg/day without TGP)
Number of subjects: 204